Kidney cancer represents approximately 4% to 5% of all cancer cases, with an estimated 646,960 individuals currently living with kidney and renal pelvis cancer in the United States. The most prevalent form is renal cell carcinoma (RCC), which accounts for about 90% of all kidney cancer diagnoses. RCC encompasses several subtypes, including clear cell, papillary, chromophobe, collecting duct, renal medullary carcinoma, translocation-associated, and unclassified variants. The disease is about twice as common in men as in women, according to the Kidney Cancer Association. The global market for kidney cancer drugs, valued at $7.31 billion in 2025, is projected to grow to $11.07 billion by 2032, based on a report from Coherent Market Insights.
The company we are profiling today is Xencor Inc. (XNCR), which is developing a novel drug for clear cell renal cell carcinoma.
For comments and feedback: editorial@rttnews.com